The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Neutrophil elastase inhibition in acute lung injury: Results of the STRIVE study
Abstract
OBJECTIVE: Neutrophil elastase is believed to be an important mediator of acute lung injury. Sivelestat (ONO-5046, Elaspol) is a small molecular weight inhibitor of neutrophil elastase. The primary objectives of this study were to determine whether sivelestat would reduce 28-day all-cause mortality or increase the number of ventilator-free days (days alive and free from mechanical ventilation from day 1 to day 28) compared with placebo in mechanically ventilated patients with acute lung injury. DESIGN: Multiple-center, double-blind, placebo-controlled trial administering a continuous infusion of sivelestat at a dose of 0.16 mg.kg(-1)hr(-1). SETTING: One hundred and five institutions in the United States, Canada, Belgium, Spain, Australia, and New Zealand. PATIENTS: A total of 492 mechanically ventilated patients with acute lung injury. INTERVENTIONS: Patients were randomized in a 1:1 fashion to sivelestat or placebo. Study drug was administered as a continuous infusion for the duration of mechanical ventilation plus 24 hrs for a maximum of 14 days. All patients were managed using low tidal volume mechanical ventilation. MEASUREMENTS AND MAIN RESULTS: The study was stopped prematurely at the recommendation of an external Data and Safety Monitoring Board, which noted a negative trend in long-term mortality rate. Final analysis revealed no effect of sivelestat on the primary end points of ventilator-free days (day 1-day 28) or 28-day all-cause mortality. There were 64 deaths in each treatment group within the 28-day study period, and the mean number of ventilator-free days was 11.4 and 11.9 in the sivelestat and placebo treatment groups, respectively (p =.536). There was no evidence of effect on measures of pulmonary function, including Pao2/Fio2, static lung compliance, and time to meeting weaning criteria. There was no difference in adverse events or serious adverse events between treatment groups. A comparison of the Kaplan-Meier 180-day survival curves showed no difference between treatment groups (p =.102), but there was an increase in 180-day all-cause mortality in the sivelestat treatment group compared with the placebo group (p =.006). CONCLUSIONS: Intravenous sivelestat had no effect on 28-day all-cause mortality or ventilator-free days in a heterogeneous acute lung injury patient population managed with low tidal volume mechanical ventilation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200005043421801 · Cited by 12,941
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Self-citationAn Expanded Definition of the Adult Respiratory Distress Syndrome
Murray, J. F., Matthay, M. A., Luce, J. M., & Flick, M. R. (1988) · American Review of Respiratory Disease · doi:10.1164/ajrccm/138.3.720 · Cited by 2,646
Smedly, L. A., Tonnesen, M. G., Sandhaus, R. A., Haslett, C., Guthrie, L. A., Johnston, R. B., Henson, P. M., & Worthen, G. S. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112426 · Cited by 567
ONO-5046, a novel inhibitor of human neutrophil elastase
Kawabata, K., Suzuki, M., Sugitani, M., Imaki, K., Toda, M., & Miyamoto, T. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)91862-7 · Cited by 359
Moraes, T. J., Chow, C.-W., & Downey, G. P. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000057842.90746.1e · Cited by 208
Posttraumatic Complications and Inflammatory Mediators
Nuytinck, J. K. S. (1986) · Archives of Surgery · doi:10.1001/archsurg.1986.01400080028004 · Cited by 156
Zeiher, B. G., Matsuoka, S., Kawabata, K., & Repine, J. E. (2002) · Critical Care Medicine · doi:10.1097/00003246-200205001-00018 · Cited by 132
Self-citationZhang, H., Downey, G. P., Suter, P. M., Slutsky, A. S., & Ranieri, V. M. (2002) · Anesthesiology · doi:10.1097/00000542-200212000-00014 · Cited by 91
Groeneveld, J., Raijmakers, P. G. H. M., Hack, E., & Thijis, L. G. (1995) · Cytokine · doi:10.1006/cyto.1995.0089 · Cited by 63
Cited by
Acute respiratory distress syndrome
Meyer, N. J., Gattinoni, L., & Calfee, C. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00439-6 · Cited by 1,144
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19
Bonaventura, A., Vecchié, A., Dagna, L., Martinod, K., Dixon, D. L., Van Tassell, B. W., Dentali, F., Montecucco, F., Massberg, S., Levi, M., et al. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00536-9 · Cited by 987
Acute lung injury and the acute respiratory distress syndrome: a clinical review
Wheeler, A. P., & Bernard, G. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60604-7 · Cited by 904
Self-citationHas Mortality from Acute Respiratory Distress Syndrome Decreased over Time?: A Systematic Review
Phua, J., Badia, J. R., Adhikari, N. K. J., Friedrich, J. O., Fowler, R. A., Singh, J. M., Scales, D. C., Stather, D. R., Li, A., Jones, A., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200805-722oc · Cited by 727
Gajic, O., Dabbagh, O., Park, P. K., Adesanya, A., Chang, S. Y., Hou, P., Anderson, H., Hoth, J. J., Mikkelsen, M. E., Gentile, N. T., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201004-0549oc · Cited by 592
Metadata
- Authors
- Zeiher, B. G., Artigas, A., Vincent, J.-L., Dmitrienko, A., Jackson, K., Thompson, B. T., & Bernard, G.
- Venue
- Critical Care Medicine
- Published
- 2004-08
- Volume
- 32
- Issue
- 8
- Pages
- 1695-1702
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2105232700
- Cited by
- 347
- References
- 10
- FWCI
- 13.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neutrophil elastase inhibition in acute lung injury: Results of the STRIVE study. https://app.cochat.ai/papers/10.1097/01.ccm.0000133332.48386.85
- The paper
- Zeiher, B. G., Artigas, A., Vincent, J.-L., Dmitrienko, A., Jackson, K., Thompson, B. T., & Bernard, G. (2004). Neutrophil elastase inhibition in acute lung injury: Results of the STRIVE study. Critical Care Medicine. https://doi.org/10.1097/01.ccm.0000133332.48386.85
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.